Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...

belongs to a class of weight loss drugs that potentially elicit greater weight loss than the popular and currently available glucagon-like peptide-1 receptor agonists (GLP-1RAs). UBT251, a so-called ...

writes one person. Others declare: “Took my first shot… have not had a drink or ... from Reddit’s weight-loss forums. Here, you will find many people rhapsodising about the benefits of ...

Originally developed to treat type-2 diabetes, GLP-1 drugs showed significant potential to treat weight loss and were approved to target obesity specifically. In the last few years, they have ...

Eli Lilly has benefitted from the windfall from tirzepatide – the active ingredient in its weight loss injection Zepbound and diabetes shot Mounjaro – which targets GLP-1 but also activates ...